Medical Oncology

Thoracic Malignancies   

Questions discussed in this category



Given the substantial risks associated with transporting an intubated and ventilated patient to Radiation Oncology, is there any evidence to support t...

This has become standard practice at our institution for patients with a good performance status, with whole brain radiotherapy given after the comple...

Specifically in O2-dependent patients? Have any dose/fractionation regimens been shown to reduce the risk of pneumonitis in this population?

In light of CheckMate 816 and IMpower010 and FDA approval for neoadjuvant chemo-nivolumab and adjuvant chemo-atezolizumab, how do you decide which sys...

NGS without any actionable mutations and PD-L1 TPS 15%. Would you offer chemotherapy, radiation, or immunotherapy and, if so, in what order?

Are there specific clinical factors, efficacy, or treatment tolerability issues that lead you to favor one agent over another? How do you compare or ...

Would you offer adjuvant atezolizumab, osimertinib, or neither? Both IMpower010 and ADAURA only had patients with EGFR exon 19 deletion or L858R mutat...

Do the results of the unplanned subset analysis of the PACIFIC trial showing no OS benefit in this population lean you away from consolidation?

Do you routinely offer post-operative adjuvant radiation in addition to chemotherapy? Are the results of the recently published negative phase II...

What factors do you use to decide between weekly low-dose carboplatin and paclitaxel combination vs cisplatin based doublet, and do you routinelt...

Are there specific patient factors for which you would more preferentially use this regimen?

Did S1800a stratify by prior treatment response? Would you choose different 2L treatment for a patient who progresses rapidlly on pembro + platinum do...

Is there anything to differentiate the two agents? CNS penetration reportedly with adagrasib, FDA accelerated approval has been given with sotorasib.&...

How does the changing landscape of first-line treatment impact your decision making for second line therapy?

I've seen a handful of fatal radiation pneumonitis associated with rapid steroid tapers by the non-treating physicians. How do you recommend prescribi...

What specific platforms do you use, individual biomarker/PD-L1 status vs NGS, tissue vs liquid or both? Must you wait for PD-L1 testing if mutation t...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?

I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clin...

How do you operationalize finding biomarker information in EHRs/testing portals, either for your own patients or if they have changed providers? If a...

Is there evidence or experience to support use of targeted therapy for KRAS G12C mutated NSCLC as first line in place of chemotherapy? 

Is this an artifact of what agent prior clinical trials used or something to do with mechanism of action (ie less mineralocorticoid effect of dex)?

How are your teams effectively evaluating and counseling patients to ensure they are prepared for potential extended adjuvant treatment approaches? Is...

Does this change for PDL1 1-49% vs >50%? Will you be more likely to employ other checkpoint inhibitors before use of HER2 targeting therapy? Or sta...

Patient has been on pembrolizumab and had two symptomatic soft tissue mass treated with radiation. 

E.g. One NSCLC with N2 disease, and additional ipsilateral small nodule that is a biopsy-proven second primary. When do you consider SBRT to a nodule ...

If a patient is asymptomatic at presentation, how do you incorporate local treatment options (RT/surgery) and when?

IMPower110 data add further support to use of checkpoint monotherapy; however guidelines continue to support either I/O monotherapy vs chemo-immunothe...

Do you consider size > 2cm, visceral pleural invasion or vascular invasion as indications for cisplatin-based chemotherapy? 

For medical oncologists, would you offer a PD-1/L1 inhibitor? For other subspecialties, how would you counsel the oncologist regarding the risk of usi...

Will degree of PD-L1 status impact your decision? Would you ever offer to stage IB patients as per study enrollment?  Do AJCC v8 staging guideli...

Is there a certain time interval where you would feel comfortable to rechallenge with immunotherapy at recurrence (6m vs 1y vs 2y?) Does degree of PDL...

Are the experts convinced by DFS when the OS is immature?  How many in BSC arm went on to receive immunotherapy and was that adequate?

What would you do for a patient with a non-EGFR actionable mutation?IMpower010 included EGFR and ALK mutated NSCLC. Is there any concern in the use of...

In elderly patients (>70-75) with a good performance status, does the risk of neurocognitive decline outweigh the benefit of PCI?

Do you initially start with systemic therapy alone or do you proceed directly to chemo-radiation? 

How are you thinking about sequencing therapies for these patients (IO vs chemo vs T-Dxd)? Are the data from DESTINY-Lung01 strong enough to warrant e...

Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use?  Do you feel the dosing used in...

What is your general rationale for selecting from available options?

If yes, do you recommend it be given concurrently with chemotherapy or sequentially? What is your target volume and dose?

Given that prophylactic cranial irradiation (PCI) has been shown to decrease the incidence of symptomatic brain metastases in patients with extensive ...

Would you prioritize the head and neck cancer or treat the lung cancer first with SBRT to take care of it first? How about if there is mediastinal inv...

Can the ipsilateral supraclavicular field and bilateral hilar nodes still be limited stage? 

How do you balance the risk of an EGFR flare while holding osimertinib vs the risk of pneumonitis when continuing?

Are two negative pleurocentesis' adequate to conclude that the patient does not have metastatic disease? Do you routinely recommend VATS and pleural b...

How do you decide between entrectinib or crizotinib? Since no head-to-head comparison, can real world datasets (such as Doebele et al) be used to comp...

Would there be any benefit to surgery in a healthy/good PS patient? There is so little data on pulmonary atypical carcinoid and radiation respons...

E.g. for a 7cm central NSCLC, would you offer 8 fx SBRT or ChemoRT? Patient is not a surgical candidate.

One example of this scenario would be a patient receiving consolidative durvalumab after chemoRT for stage III NSCLC who develops a new peripheral lun...

Although a small subset, do you generally move these patients directly on to chemotherapy +/- immunotherapy or does it depend on the specific mutation...

Patient has been treated with carbo/etop/atezo, WBRT, and maintenance atezo. Currently on high-dose steroids. Would you consider hospice or trial chem...

If starting with entrectinib would you still try crizotinib, or move to lorlatinib or another novel TKI? Or change entirely to chemotherapy, immunothe...

Is there any role of radiation therapy for these patient for symptomatic relief? 

Would you consider afatinib? Afatinib has shown some activity in NRG1 fusion + patients but amplifications is unclear. 

Given recent data in Blood (Moik et al, 2021), and the potentially overlapping risks with other clinical factors associated with NSCLC. Will you alte...

The ALTA and ALEX trials showed better PFS with brigatinib v. crizotinib and alectinib v. crizotinib. How do you choose your first...

Would you test for resistance mutations in this setting, using blood-based sample if no progression outside CNS?

What is the current data regarding acquired resistance mutations for ALK?  Should newer agents such as lorlatinib be reserved for later lines a...

If so, would you recommend adjuvant chemotherapy and PCI after?

Are you routinely performing molecular sequencing? Would you modify your treatment approach in first or later lines based on PDL1 status?

Do you aim to give a total of 26 doses or do you stop at one year from first dose no matter how many were given?

Would you consider it for a patient who had bulky thoracic disease, with limited extrathoracic disease at diagnosis and achieved a CR after induction ...

How do you decide between supportive care v. chemoimmunotherapy? Is there a threshold of disease burden that would push you towards recommending hospi...

As SCLC in never smokers is extremely rare, do you consider NGS testing, or do you modify treatment in any way?

 Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients  th...

What clinical factors do you take into consideration? Would you recommend chemo-immunotherapy regimens for a fit patient who relapses at 6 mos post-t...

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

Conversely: In a patient with N2 EGFR+ NSCLC receiving radiation, would you still consider use of osimertinib?

Are there any data to support a specific TKI therapy for non-T790M exon 20 mutations/insertions?

Would you differentiate between patients with measurable disease vs NED?  Are there specific data to guide us?

What was the magnitude of benefit for patients with EGFRm NSCLC by stage?  Are you still considering adjuvant osimertinib for patients with earl...

Are there scenarios in which you would proceed with checkpoint inhibitor for PDL1+ disease before having full molecular testing results?

Are you performing repeat molecular sequencing after progression on targeted therapy? If so, are you obtaining tissue biopsy vs liquid platform?

If patients do recur, do you perform these tests on the initial surgical specimen or on tissue from a fresh biopsy (or both?)

Is data available regarding the percentages of patients in each arm who underwent staging PET or the breakdown of CNS imaging modalities?

Are the rates of adjuvant chemotherapy used in ADAURA consistent with real-world practice?

Assuming no clinical trial, no actionable mutation, and PD-L1 < 50%, do you consider the patient to be primary refractory to platinum and move to s...

For T2bN0 or T3N0 disease, you consider radiation alone, sequential radiation followed by chemotherapy, or concurrent chemoradiation?

After initiation of anti-TB treatment and 3 negative AFB smears, would you initiate concurrent chemoRT? Would you give sequential RT then chemo to giv...

Does the recent CROWN trial affect your first line treatment decision? 

No primary thoracic mass identified. Knowing these often following an aggressive clinical course, would you consider concurrent chemo/RT, incorporate ...

Following chemoradiation, would you consider maintenance durvaluamb as for NSCLC even given the SCLC component? 

Would you modify the radiation dose or field in this setting? Would you pre-emptively dose reduce chemotherapy, or modify the dosing of ruxolitinib?

Would you offer SBRT to both sites, SBRT to the primary and standard fractionation to the node due to proximity to the main bronchus/proximal lobar br...

Does the reported positive endpoint in OS for Checkmate 743 change your practice?

The patient remains without evidence of systemic disease outside of the CNS on serial imaging. Would you continue treating with SRS as lesions appear,...

Topotecan, nivolumab/ipilimumab and others are listed within NCCN guidelines, and lurbinectedin was recently approved in this space. How do you decide...

The recent NELSON trial evaluates screening in a slightly different population than the USPSTF/NLST criteria. Which will you follow?

How do you balance risk of chemo after surgery with risk of progression of disease while waiting for healing after surgery before starting chemo?

Does the availability of first line checkpoint inhibitor therapy affect your treatment decision? 

Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?

What are the risks of infection with COVID-19 if using immunotherapy?  

How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...

Are there specific mutations or co-mutations were you would consider use of this agent? 

Should staging and treatment decisions be made based on imaging alone?

How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...

Many commercial testing assays report on EGFR gene amplification in addition to the known sensitizing mutations. Are there any data that this can be u...

Would you treat with chemotherapy (carboplatin/etoposide) vs anti-pd-1 monotherapy vs combination chemoimmunotherapy vs supportive care?

Keynote 407 recently published data on pembrolizumab +/- chemo for metastatic squamous cell lung cancer.  The confidence interval for the group w...

Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?

Especially if you don't have trials available at the moment. Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line ge...

Our medical oncology team wants to give a patient Vitamin B12 and Folate 1 week before chemo- do we need to push back the RT start date to start both ...

How do you approach this given the limited # of patients this applies to?  Checkmate 017 and 057 only had 5-7% of patients still on nivolumab at ...

In patients who have a mixed response or progression and are poor candidates for other systemic agents, would you consider consolidating the chest? Wo...

In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?

Are the other options of chemotherapy that can be used instead of platinum based doublets, including with paclitaxel? 

Would you consider first line treatment with somatostatin analog or Lu 177 dotatate? Is observation an option for asymptomatic patients?

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...

Would you suspect progressive disease v. radiation necrosis vs optic neuritis due to immunotherapy. Eyes were within radiation field 8 months ago.&nbs...

The NCCN guidelines regard  MET exon 14 skip mutation   as an emerging biomarker but no formal recommendation to start crizotinib. If high P...

Are there any biomarkers that would affect your decision for first line PD-1 therapy (including but not limited to STK11)? 

1st-line pembrolizumab is supposed to be used AFTER failure of appropriate targeted agents in this setting, but would you consider the reverse sequenc...

For instance, not chronic autoimmune diseases (eg RA, IBD) that may relapse/remit but events like Guillan Barre syndrome that is not likely to recur b...

Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/pa...

With the recent finding of benefit of pembrolizumab and SBRT (PMID: 31294749), would you consider "adjuvant" pembrolizumab for PDL1 positive patients?...

Do you recommend or make any modifications in the PACIFIC regimen for patients > 75 years of age?

Would you reserve TKI for after standard of care chemotherapy and immunotherapy or consider earlier line of treatment?

In clinical practice, consolidation chemotherapy is sometimes used, though this was not implemented in the PACIFIC trial.Antonia et al., PMID 28885881...

Would this approach be different for a patient treated with tri-modality therapy (ie neoadjuvant chemoradiation followed by resection)?

Given the prior results of Keynote 189, how do you plan to utilize the data from Keynote 042 with pembrolizumab monotherapy?  

Or do you reserve in case of oligo-progression or progressive/symptomatic disease? 

What are the major factors that impact your decision? If you opt for surgery, what factors impact your decision to offer RT preoperatively vs. postope...

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.

Do you feel it is important to start durvalumab within 14 days of completing cCRT?  What real life challenges do you face in doing so and wh...

Medical inoperability is clearly defined, anatomical resectability is also pretty much clear (invasion of trachea/carina/esophagus, etc). But what abo...

Would you treat to the GEJ regardless of whether the positive node was identified in the upper portion of station 8? Do surgeons routinely dissect to ...

NCCN guidelines recommend adjuvant chemotherapy for patients with stage 2 or 3 R0 resected NSCLC including 4 cycles of platinum based chemotherapy, bu...

Do you consider specific pre-medications, an alternate checkpoint inhibitor, or abandon ICI altogether? 

Retrospective studies (PMID: 29935305, PMID: 30125216) have shown a correlation between poorer outcome and baseline steroid use in patients treat...

If you are using a standard 30/10 fractionation, is there a benefit to keeping chemo on board for radio-sensitization?

Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung canc...

First line pembrolizumab is only approved after progression on TKI - but would you ever offer chemo-immunotherapy prior to target therapy? 

Is the timing of progression (in relation to chemoradiation) a factor, and is there any role for repeat PD-L1 testing at the time of progression?

The FDA has approved the new dosing schedule of Nivolumab 480 mg every 4 weeks for multiple disease sites (melanoma, RCC, urothelial carcinoma, SCC of...

For the first treatment day (during combined chemo/XRT courses), is it ok to give XRT first then send the patient for chemo or should the chemo be giv...

Would you consider adding atezolizumab to a cisplatin/irinotecan regimen, or cisplatin instead of carboplatin?

No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.

There is no primary and no distant disease seen on restaging PET. RTOG 0236 shows significant regional failure rate. Some have reported salv...

Do you recommend or withhold influenza and pneumonia vaccines while on treatment with checkpoint inhibitors?

Since the randomized phase II data from Gomez et al presented at ASTRO 2018 showed a survival benefit, is there concern about randomizing patients to ...

If there is no other evidence of metastatic disease, would you offer thoracic radiation? Either upfront with chemo or after initial system therapy if ...

The NCCN guidelines suggest surgery can be considered for up to T3N2 NSCLC after a period of induction chemotherapy/chemo-radiation without progressio...

Is this recommended in a certain subset of patients (EGFR positive or 1 metastasis only)? Or should we await maturation of the MD Anderson/Colorado/On...

Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?

Prior to the PACIFIC trial, patients were treated with definitive chemo/rads. With local recurrence <1yr after chemorads and definitive treatment f...

Would starting with chemotherapy be preferred in this situation and consider concurrent radiation, then switch over to Pembrolizumab once some control...

There is no evidence of disease outside the lung on PET, and the patient is completely asymptomatic with negative EGFR, ALK, ROS1, and BRAF and a PD-L...

PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?

For example, would a + vascular margin, extranodal extension of N1 disease, translobar disease, or high risk histologies (large cell neuroendocrine, s...

Would you repeat PET or is it adequate to change to CT surveillance? Although surveillance PET/CT is not recommended by NCCN guidelines, these are oft...

Would you treat with localized therapy with chemoradiation or SBRT or consider ROS-1 directed therapies? 

Would you use the same schedule as early stage NSCLC primary?

The current NCCN guidelines reserves radiation for patients who are not resectable after induction chemotherapy. Does it make sense to offer concurren...

Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would ...

Would your choice of treatment change if the same patient was T790M negative and osimertinib was given as a first-line therapy?

Do you prefer carboplatin-paclitaxel-bevacizumab, carboplatin-pemetrexed-pembrolizumab, or chemotherapy alone?

Does the more recent NEJ026 trial describing benefit from Bevacizumab plus Erlotinib over Erlotinib alone in patients with EGFR driver mutations ...

Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...

If there are 3 negative scans, do you continue annual screening?

A recent phase III trial published in JCO describes the NVALT-11/DLCRG-02 study, evaluating PCI vs observation in patients with stage III NSCLC s/p co...

Specifically, would carbo-taxol-bev-atezo (IMpower 150) be an attractive option given the activity of bev-atezo in sarcomatoid PDL1+ metastatic RCC (I...

For the Impower 150 trial, is there data reported on PFS and OS for ABCP vs ACP (atezolizumab/bevacizumab/carboplatin/paclitaxel vs atezolizumab/carbo...

Or would you wait to start coincident with the start of cycle 2? If a shorter time from the start of any therapy to the end of radiation (SER) is sign...

Can SRS or whole brain radiotherapy be reserved for progression in these young, healthy patients?

By the definition this would be M1 disease, but would definitive treatment be appropriate? Is there clear data that a single pleural nodule has no cha...

Would you consider "aggressive" concurrent chemoradiation followed by SRS to the CNS lesion and possible consolidative immunotherpay (the PACIFIC...

Would you consider MS an absolute contraindication to this treatment?

Given the results of Keynote 189, is there any benefit of chemotherapy+pembrolizumab in specific subsets of patients in the first line setting?

In the absence of clinical trial, is there are role for dose-escalating alectinib, or would you consider brigatinib or chemotherapy?

When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?

These patients have been largely excluded from these trials.  What if the infection is well controlled?

Do you increase dosage of the TKI or switch to a different generation TKI?  How does your answer differ for EGFR vs. ALK, and for discerete brain...

Assuming it is clinically indicated, would a checkpoint inhibitor be efficacious in a patient who has a concurrent autoimmune illness (PMR/TA) and is ...

Would you ever considering re-starting immunotherapy before completing the taper? According to the new guildelines on managing immunotherapy related ...

If you treat pre-chemotherapy volumes, is there a benefit to induction chemotherapy even in bulky disease. If so, how do you define disease that ...

What factors influence your decision (R1 v. R2 resection? T stage?) If sequential, do you typically prefer radiation before or after chemotherapy?

Can T790M mutation develop within this early time frame, or are these perhaps patients who may benefit from switch to chemotherapy?

Or do you recommend treatment with systemic therapy alone, as this represents Stage IV disease?

Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?

How does this approach change with mediastinal lymph node involvement? What are the indications for definitive or adjuvant radiotherapy +/- chemothera...

What is the best evidence for what dose to use? When would you give it in relation to the checkpoint inhibitors? Which metastatic sites do you choose ...

How do you select between the available treatment options (gemcitabine, docetaxel, paclitaxel, nab-paclitaxel) in combination with platinum?  Up...

When there is biopsy proven mediastinal disease, do you offer definitive chemoradiation and monitor, or do you try to prove the presence/absence ...

Has the recent FDA approval of dabrafenib/trametinib changed your practice?

Have the results of LUX-Lung 7 changed your routine practice? Are there promising up-front clinical trials that these patients may benefit from?

Do you incoprate Ki67% or mitotic rate into your treatment decision, and is there any use for somatostatin based imaging such as octreoscan or gallium...

Should we be routinely sequencing ALK to select an ALK inhibitor with the appropriate efficacy, matched to resistance patterns?

For instance with isolated progression at one metastatic site, with all other disease stable and clinically doing well. 

How do the different assays compare when choosing a specific immunotherapy, and does this change for first vs second (or beyond) line of therapy?

How long do you typically wait before starting consolidation chemotherapy, and do you routinely perform re-staging scans prior to consolidation? 

What immunosuppressive agents are used and in what order?  Does your approach differ depending on the organ involved, e.g. colitis vs. pneumoniti...

In addition to addresing the brain met (surgery vs. SBRT), would you proceed with systemic "adjuvant" chemotherapy, or would you treat the patient as ...

 Is there any data to support this approach? If not, are there trials you are aware of looking at "rescuing" these patients with a different chec...

Does the extent/duration of systemic disease control (complete response vs. stable disease, for example) influence your decision?  What about whe...

Does the risk of severe inflammation of the liver lead you to choose other therapies in in this population?  What about in patients with mild liv...

If these are presumed to be immune-mediated (e.g. immune neutropenia or immune thrombocytopenia), do you treat with steroids?

The Phase III J-ALEX study and two phase II studies seem to suggest favorable intracranial response rates for alectinib. 

If PET/CT is unrevealing for a primary source, would you treat such a patient with platinum-etoposide or monitor closely until further disease progres...

Does recent data from the OAK study showing a survival benefit for atezolizumab over docetaxel even in non-smokers affect your decision making?  

Based on recently published data from CheckMate 032, do you now offer nivolumab to small cell patients who have progressed after first-line chemothera...

Does the type of autoimmune disease (ex IBD, rheumatoid arthritis, interstitial lung disease) matter?

4cm has historically been used as the cutpoint for determining benefit from adjuvant chemotherapy in this population (Strauss et al, JCO 2008; Bu...

Although PD-1 inhibitors are now standard of care for second-line therapy of advanced NSCLC, there remains the question of which therapy is best to us...

Would you offer adjuvant TKI following ADAURA data?  Or proceed with durvalumab based on PACIFIC data?

As it is suggested for larger tumors treated with surgery, based on post hoc CALGB analysis?

The NCCN guidelines discourage the use of PET/CT surveillence but the recent analysis of RTOG 0235 found post-CRT PET uptake to be associated with wor...

Based on the European data published in the Lancet (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961085-0/abstract), are you s...

For example, should nivolumab be considered standard second-line therapy for adenocarcinoma patients?   Can it be considered for first-line thera...

I am aware that chemotherapy can obviate the need for RT in patients with SVC syndrome, but I'm not sure if this can be extrapolated to spinal cord co...

Should mutations other then EGFR and ALK be routinely tested for? Should next generation sequencing be routinely done?

I've read about patients who were treated with concurrent bevacizumab-RT who developed lethal tracheoesophageal fistulas. How long would you have to w...


Papers discussed in this category


International journal of radiation oncology, biology, physics, 2013-09-01

Int. J. Radiat. Oncol. Biol. Phys., 2006-09-01

Journal of cancer research and therapeutics, 2012

International journal of radiation oncology, biology, physics, 2012-05-01

Neurosurgery, 2013-10

Practical radiation oncology, 2015

J. Neurosurg., 2005-01-01

J Korean Neurosurg Soc, 2011-08-01

Radiat Oncol, 2014-07-08

BMC Cancer, 2015-03-04

Acta Neurochir (Wien), 2013-01-01

International journal of radiation oncology, biology, physics, 2011-11-01

N Engl J Med, 2007 Aug 16

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017-12

Lancet Oncol., 2017-05-01

The New England journal of medicine, 1999-08-12

BMC Cancer, 2015-08-15

The Lancet. Oncology, 2009-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-04-01

J Clin Oncol, 2011 Jan 10

JAMA, 2016-07-26

Radiation oncology (London, England), 2014-09-30

Cancer, 2016-06-15

J. Clin. Oncol., 2018 May 22

Lung cancer (Amsterdam, Netherlands), 2018-06

The New England journal of medicine, 2018-08-23

The New England journal of medicine, 2018-12-06

International journal of radiation oncology, biology, physics, 2019-04-01

Lancet, 2019 Oct 04

JAMA oncology, 2019-06-01

International journal of radiation oncology, biology, physics, 2019-04-01

International journal of radiation oncology, biology, physics, 2019-04-01

Neurosurgery, 2019 Oct 10

JAMA Oncol, 2020 Jun 4

J Clin Oncol, 2020 Aug 10

Lung Cancer, 2014 Aug 02

N Engl J Med,

Lancet Oncol, 2020 Apr 03

Int J Radiat Oncol Biol Phys,

JAMA,

J Neurosurg,

Cancer,

J Clin Oncol, 1999 Jul

Lancet, 2015 Jan 3

N Engl J Med, 2014 Sep 27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-10

Lancet, 1998 Jul 25

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-07-01

International journal of radiation oncology, biology, physics, 2012-06-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

Int. J. Radiat. Oncol. Biol. Phys., 1999-08-01

Radiat Oncol, 2015 May 27

International journal of radiation oncology, biology, physics, 2016-06-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01

The New England journal of medicine, 2016-11-10

The New England journal of medicine, 2018-01-11

N. Engl. J. Med.,

Journal of the National Comprehensive Cancer Network : JNCCN, 2018-10

JAMA Netw Open, 2019 Aug 2

Pract Radiat Oncol, 2020 May - Jun

J Thorac Oncol, 2021 Feb 02

J Clin Oncol, 2021 Jan 27

Int J Radiat Oncol Biol Phys, 2020 Nov 18

J Clin Oncol, 2021 Aug 11

The New England journal of medicine, 2015-10-22

International journal of radiation oncology, biology, physics, 2015-11-01

Eur. J. Nucl. Med. Mol. Imaging, 2014-06-01

The Lancet. Oncology, 2015-02

Semin Radiat Oncol, 2015 Oct

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-11-01

Practical radiation oncology, 2013

International journal of radiation oncology, biology, physics, 2017-02-01

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019-02

Technol Cancer Res Treat,

Am J Clin Oncol,

N. Engl. J. Med., 1999-01-28

Lancet Oncol., 2017 Jun 20

The oncologist, 2016-02

Clinical lung cancer, 2017-11

Lancet Oncol., 2014 May 13

The Lancet. Oncology, 2015-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-01

N Engl J Med, 2014 Mar 27

N Engl J Med, 2013 Jun 20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-11-01

The Lancet. Oncology, 2016-07

Lancet (London, England), 2009-08-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-07

Journal of the National Cancer Institute, 2007-03-21

The Lancet. Oncology, 2015-07

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

JCO Precision Oncology, 2017 Sep 29

Sci Rep, 2014 Sep 09

Medicine (Baltimore),

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-01

Cancer Treat. Rev., 2016-04-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

Clin. Cancer Res., 2015-04-15

Lancet (London, England), 2016-04-09

Eur. J. Cancer, 2016-02-01

Lancet Oncol., 2014-10-01

Lancet Oncol., 2011-08-01

Clin Lung Cancer, 2018 Nov

The Lancet. Oncology, 2016-12

N Engl J Med, 2017 Nov 16

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-05-01

Medical and pediatric oncology, 1990

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986-01

Immunotherapy, 2016-10

J. Clin. Oncol., 2020 Feb 14

Neuro Oncol,

J Clin Oncol, 2021 Aug 11

International journal of radiation oncology, biology, physics, 2011-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-01-01

Cancer, 2013-11-01

Journal of geriatric oncology, 2015-03

International journal of radiation oncology, biology, physics, 2013-07-15

Advances in radiation oncology, 2017

The Lancet. Oncology, 2009-05

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017-02

Cancer, 2010 Aug 27

J Clin Oncol, 2008 Dec 01

J Thorac Oncol,

Clin. Cancer Res., 2015 May 27

Lancet (London, England), 2017-01-21

The New England journal of medicine, 2018-06-14

The Lancet. Respiratory medicine, 2019-05

Ann. Oncol.,

J Thorac Oncol, 2017-02-01

JAMA oncology, 2017-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-07-15

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012-11

Lancet, 2014-09-20

The New England journal of medicine, 2018-05-31

Lancet, 2011-09-17

Radiographics : a review publication of the Radiological Society of North America, Inc, 2014-10

Oncotarget,

Nature, 2017-04-26

Cancer discovery, 2017-12

Cancer discovery, 2016-10

Arthritis & rheumatology (Hoboken, N.J.), 2018-03

The Lancet. Oncology, 2016-11

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017-10

J Thorac Oncol, 2016 Oct 07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-04-01

J. Natl. Cancer Inst.,

J. Clin. Oncol.,

The New England journal of medicine, 2017-06-22

Journal of the National Cancer Institute, 2016-09

Thorac Cardiovasc Surg, 2015 Dec 15

Science translational medicine, 2013-12-18

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-02

The New England journal of medicine, 2018-05-31

The New England journal of medicine, 2018-12-13

The New England journal of medicine, 2006-12-14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-01

J Thorac Oncol,

Pulmonary medicine, 2012

Radiat Oncol, 2015 Apr 26

The New England journal of medicine, 2018-11-22

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-10

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017-06

Clin. Cancer Res., 2016 Feb 04

Clin Lung Cancer, 2017 Jul 10

J Thorac Oncol,

Clinical lung cancer, 2018-07

Int. J. Radiat. Oncol. Biol. Phys., 2017 Mar 15

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016-06

Annals of internal medicine, 2018-01-16

Neuroendocrinology,

J Gastrointest Cancer,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-12-10

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-04

Surgery,

The Annals of thoracic surgery, 2015-12

The Journal of thoracic and cardiovascular surgery, 2016-05

Lancet (London, England), 2014-08-23

Lancet Oncol, 2019 May 20

Cancer Discov,

Clin. Cancer Res.,

N. Engl. J. Med.,

Practical radiation oncology, 2018

Br. J. Cancer,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-09-01

American journal of clinical oncology, 1997-06

The Annals of thoracic surgery, 2015-02

Thorac Cardiovasc Surg,

The Lancet. Oncology, 2017-07

International journal of radiation oncology, biology, physics, 2017-06-01

JAMA oncology, 2018-01-11

The Lancet. Oncology, 2015-07

J. Clin. Oncol., 2019 Dec 11

Oncologist, 2015 Sep 09

J Thorac Oncol, 2016 Jul

J Thorac Oncol, 2018 Feb

The New England journal of medicine, 2017-08-31

Ann Oncol, 2020 May 11

N Engl J Med,

J Clin Oncol, 2020 Aug 11

J Thorac Oncol,

The Lancet. Oncology, 2015-02

J. Clin. Oncol., 2017 Dec 14

J. Clin. Oncol., 2018 Jun 15

The Lancet. Respiratory medicine, 2017-11

JAMA Oncol,

Lung Cancer,

Lancet Oncol., 2008 Jun 24

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016-09-15

J. Clin. Oncol., 2018 Mar 29

Lancet (London, England), 2009-03-28

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-09

N Engl J Med, 2020 Sep 19

Lancet, 2021 Sep 20

J Clin Oncol, 2020 Dec 17

J. Clin. Oncol., 2020 Feb 20

J Clin Oncol, 2019 Jun 02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-03-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-01-10

JAMA Oncol,

Lancet Oncol, 2021 Dec 15

Arch Surg,

Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01

Journal of oncology, 2018

Clin. Cancer Res., 2017 Oct 24

JAMA oncology, 2017-05-01

International journal of radiation oncology, biology, physics, 1994-06-15

International journal of radiation oncology, biology, physics, 2010-12-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010-06

JAMA oncology, 2019-05-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-11-01

International journal of radiation oncology, biology, physics, 2015-07-01

Tumori, 2018 May 08

Advances in radiation oncology, 2017

J. Clin. Oncol., 2017 Oct 02

J. Clin. Oncol., 2015 Nov 02

Radiographics : a review publication of the Radiological Society of North America, Inc, 2004

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-03

The New England journal of medicine, 2015-07-16

International journal of radiation oncology, biology, physics, 2015-09-01

Future Oncol, 2019 Apr 25

N. Engl. J. Med., 2017 Jun 04

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-04-15

The New England journal of medicine, 2005-06-23

Lancet Oncol., 2006-09-01

N. Engl. J. Med.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-01-01

J Thorac Oncol, 2019 Jan 18

Nat Commun, 2019 Mar 27

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019-08-01

Lung Cancer, 2017 Jun

J Thorac Oncol, 2020 Sep 08

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20

Lancet, 2019 Apr 11

JAMA Oncol, 2019 Jul 11

JAMA Oncol, 2019 Jul 11

Cancer Res., 2017 Feb 15

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-05

The Annals of thoracic surgery, 2019-08

Eur. Respir. J., 2017 Jun 01

Clin. Cancer Res., 2018 Oct 08

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019-02

International journal of radiation oncology, biology, physics, 2018-03-15

J Thorac Oncol, 2019 Feb 16

Cancer discovery, 2017-04

Radiation oncology (London, England), 2014-09-19

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-01

International journal of radiation oncology, biology, physics, 2018-08-01

Int. J. Radiat. Oncol. Biol. Phys., 2016 Jul 15

Eur. Respir. J., 2018 Jan 04

Practical radiation oncology, 2018

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016-08

J Thorac Dis,

J. Clin. Oncol., 2012 Apr 02

Semin. Cancer Biol., 2019 Jul 19

J Natl Compr Canc Netw,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-01-10

Clinical lung cancer, 2017-07

Int. J. Radiat. Oncol. Biol. Phys., 2020 Feb 07

Cureus, 2019 Jun 22

Lung Cancer, 2009 Jan 24

Radiat Oncol, 2016 Dec 03

The Journal of molecular diagnostics : JMD, 2018-03

Ann. Oncol.,

Lancet Oncol., 2012 May 22

Science (New York, N.Y.), 2015-04-03

JAMA, 2014-05-21

Cancer, 2005-04-15

Lung cancer (Amsterdam, Netherlands), 2015-12

Nature medicine, 2018-05

Cancer, 2017-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-20

Lancet (London, England), 2019-05-04

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-07

European journal of cancer (Oxford, England : 1990), 2019-03

Lung Cancer, 2012 Feb 10

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

N. Engl. J. Med., 2019 Sep 28

Clin. Cancer Res., 2019 Aug 15

Ann. Oncol.,

Case reports in oncology, 2017

BMC Cancer, 2015 Oct 15

Cancer, 2011-11-01

Lancet Oncol., 2017 Sep 25

The New England journal of medicine, 2011-08-04

N. Engl. J. Med., 2020 Jan 29

The New England journal of medicine, 2014-11-13

Lancet Oncol., 2017 Sep 11

JAMA Netw Open, 2020 Feb 05

N Engl J Med, 2021 Sep 18

Cancer discovery, 2015-08

Annals of oncology : official journal of the European Society for Medical Oncology, 2018-10-01

Nature, 2014-07-31

Cancer discovery, 2015-08

J Clin Oncol, 2020 May 10

J Thorac Oncol, 2021 Oct 12

The New England journal of medicine, 2012-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01

J Clin Oncol, 2020 Dec 04

J Clin Oncol, 2020 May 29

J Clin Oncol, 2021 Jan 13

Lancet Oncol, 2020 Dec 04

Lung cancer (Amsterdam, Netherlands), 2017-10

Curr Oncol, 2020 May 01

Mol Cancer, 2020 Sep 11

PLoS One, 2018 Aug 28

J Clin Oncol, 2020 Sep 10

J Thorac Dis,

Ann. Oncol., 2015 Apr 28

Cancer Sci., 2016 Aug 09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

J. Thorac. Cardiovasc. Surg.,

Cancer, 2015 Jan 06

Eur J Cardiothorac Surg,

JCO precision oncology, 2019

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2016-07

Clin Lung Cancer, 2020 Feb 10

Lancet Oncol.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-01-20

J Thorac Oncol, 2019 Nov 18

Journal of the National Cancer Institute, 2011-10-05

BMC Cancer, 2018 Oct 12

Br J Cancer,

The New England journal of medicine, 2016-03-03

Cancer immunology, immunotherapy : CII, 2017-01

Cancer, 2017-06-01

Journal of the American Academy of Dermatology, 2019-07-11

J Immunother,

Oncologist, 2020 Feb 11

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-09

J Thorac Dis,

Clin Oncol (R Coll Radiol), 2017 Nov 16

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-08

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-06

Radiother Oncol, 2020 Jul 31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-06-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20

J. Clin. Oncol., 2020 Jun 02

Ann Oncol, 2020 Sep 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999-02

Lancet Oncol, 2020 Mar 27

Lancet Oncol,

J Thorac Oncol. , 2019 Oct 17

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-01

Cancer Cell, 2018 May 03

Expert Opin Emerg Drugs, 2020 Aug 04

Lung Cancer, 2020 Sep 10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-02-01

Cancer Epidemiol Biomarkers Prev, 2012 Apr 26

Lancet Oncol, 2021 Dec 15

Nature, 2019 Oct 30

N Engl J Med, 2021 Jun 04

Cancer Med, 2021 Jan 19

JAMA oncology, 2018-02-01

J Immunother Cancer,

Cancer discovery, 2015-08

The New England journal of medicine, 2018-11-22

Lancet, 2017 Jan 24

N Engl J Med, 2020 May 14

J Clin Oncol, 2020 Jun 18

Clin Lung Cancer, 2021 Jan 27

Case Rep Oncol, 2019 Oct 09

J Clin Oncol, 2019 Dec 06

The Lancet. Oncology, 2014-09

Cancer Sci,

Lancet Oncol, 2021 Jan 18

ESMO Open, 2021 Oct 01

J Clin Oncol, 2021 Apr 19

Lung cancer (Amsterdam, Netherlands), 2012-12

N Engl J Med,

Blood,

Cancers (Basel), 2019 Dec 25

Lancet,

J Thorac Oncol, 2021 Jul 08

J Clin Oncol, 2021 Jan 29

J. Clin. Oncol., 2006-03-01

The New England journal of medicine, 1992-12-03

Ann Oncol,

J Clin Oncol, 2021 Mar 08

J BUON,

Br J Cancer, 2019 Sep 30

J. Clin. Oncol., 2008-07-20

The Lancet. Oncology, 2017-12

Ann Oncol, 2019 Oct 1

Int J Cancer, 2020 Dec 21

Adv Ther, 2020 Oct 29

J Thorac Oncol, 2016 Apr 16

J Thorac Oncol, 2018 Jun 05

J Clin Oncol, 2021 Mar 01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-11

JAMA, 2010-03-17

International journal of radiation oncology, biology, physics, 2015-06-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20

Chest, 2003-11

J Immunother Cancer,

Oncotarget, 2018 Feb 22

J Thorac Oncol,

The Lancet. Oncology, 2017-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-20

JAMA Oncol,

Eur J Cancer, 2021 Apr 01

Lancet Oncol, 2019 Oct 25

Immunotherapy, 2019 Jun 12

Nat Rev Clin Oncol, 2020 Aug 05

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-01

Future Oncol, 2018 Nov 08

World J Clin Cases,

Br J Cancer, 2016 Nov 22

Biochemistry, 2015 Jul 06

N Engl J Med, 2019 Nov 21

Lancet Oncol, 2016 Apr 12

Ann. Oncol., 2010 Jan 29

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2017-08-01

Eur J Cardiothorac Surg, 2014 Nov 18

J Thorac Cardiovasc Surg, 2019 Sep 30

Nephron,

ESMO Open, 2017 Jul 19

Ann Oncol,

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011-10-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

Lung Cancer, 2020 Nov 13

Neuropathology, 2019 Mar 13

Respir Investig, 2014 Nov 13

Lancet, 2021 Jan 21

Ann Oncol,

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-01

J Thorac Oncol, 2019 Nov 19

Future Oncol, 2021 Feb 11

J Thorac Oncol, 2020 Jan 13

J Immunother Cancer, 2019 Jan 21

ESMO Open, 2021 Aug 31

J Thorac Oncol, 2020 Apr 30

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10

Ann Oncol, 2021 Apr 22

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-04

J Thorac Oncol, 2021 May 05

JACC CardioOncol, 2019 Dec 17

J Clin Oncol, 2021 Nov 02

J Thorac Oncol, 2021 Mar 04

JTO Clin Res Rep, 2021 Mar 09

J Transl Med, 2019 Feb 21

Lung Cancer, 2020 Jun 06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-20

J Immunother Cancer,

Am Soc Clin Oncol Educ Book,

N Engl J Med, 2022 Apr 11

Ann Pharmacother, 2021 Jul 20

Ann Transl Med,

Can Fam Physician,

Ann Oncol, 2013 Mar 01

Cancer Discov, 2021 Sep 21

Translational oncology, 2019-02

J Clin Oncol, 2022 Jun 03

N Engl J Med, 2022 Jun 03

J Thorac Oncol, 2017 Oct 31

Clin Cancer Res, 2010 May 11

Cancer Chemother Pharmacol, 2014 Jun 17

International journal of radiation oncology, biology, physics, 2015-06-01

N Engl J Med, 2021-04-01

Lancet Oncol,

Nat Rev Clin Oncol,

Oncology, 2020 May 28

Metal-based drugs, 2010

J Allergy Clin Immunol Pract, 2019 Feb 15

Ann Oncol, 2022 Feb 14

FEBS J, 2009 Nov 18

Clin Lung Cancer, 2018 May 01

J Thorac Oncol, 2021 Feb 01

Journal of immunotherapy (Hagerstown, Md. : 1997), 2018-05

Neurology, 2019 Mar 08

Front Immunol, 2022 Aug 22

Chest, 2020 Aug 14

Chest, 2020 Jul

ERJ Open Res, 2020 Oct

EClinicalMedicine, 2022 Aug 11

J Thorac Oncol, 2013 Nov

Practical radiation oncology, 2011